【制药网 医药股市】近日，浦银国际证券发布研报称，给予恒瑞医药“买入”评级，目标价格为80元。该机构给予“买入”评级的理由主要包括：3Q25 收入和净利润不及市场预期；其推算三季度许可收入约 1 亿元，产品收入约 73 亿元，其中创新药收入约 40 亿元。风险提示：销售不及预期、竞争激烈、研发延误或失败、国际化进展不及预期、利润不及预期。恒瑞医药2025年三季报显示，其营收、净利继续稳步增长：实现...
Source Link【制药网 医药股市】近日，浦银国际证券发布研报称，给予恒瑞医药“买入”评级，目标价格为80元。该机构给予“买入”评级的理由主要包括：3Q25 收入和净利润不及市场预期；其推算三季度许可收入约 1 亿元，产品收入约 73 亿元，其中创新药收入约 40 亿元。风险提示：销售不及预期、竞争激烈、研发延误或失败、国际化进展不及预期、利润不及预期。恒瑞医药2025年三季报显示，其营收、净利继续稳步增长：实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.